The same monitoring REGENXBIO added after one hold is what caught the finding behind this one
FDA placed a new clinical hold on REGENXBIO's Hunter syndrome therapy after asymptomatic spine findings in 5 of 48 trial participants.
The monitoring that caught them was added after an earlier, unrelated hold on a different drug.
REGENXBIO's RGX-121, a gene therapy for Hunter syndrome, is under a new FDA clinical hold. Five of 48 participants in its CAMPSIITE trial developed asymptomatic spine findings years after treatment, and every investigator and radiologist involved calls them likely benign.
The finding didn't come from a routine check. It came from monitoring REGENXBIO only added after an earlier, unrelated hold on a different drug. That fix is now the reason this one is paused too.
What happened
On August 24, 2026, REGENXBIO (Nasdaq: RGNX) announced a new FDA clinical hold on RGX-121 (clemidsogene lanparvovec). RGX-121 is its investigational gene therapy for Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome.
RGX-121 is partnered with NS Pharma.
The hold followed the discovery of asymptomatic spine MRI findings, a small nodule or small cystic mass, in five participants in REGENXBIO's CAMPSIITE® trial. REGENXBIO says it does not expect to resubmit RGX-121's Biologics License Application (BLA) in the near term.
The hold, at a glance
- Drug: RGX-121 (clemidsogene lanparvovec), a one-time AAV gene therapy for Hunter syndrome, partnered with NS Pharma.
- What was found: a small nodule or small cystic mass on spine MRIs of 5 of 48 CAMPSIITE trial participants, 3 to 6 years after treatment.
- How it reads: investigators call the findings nonserious; radiologists believe they are likely benign; REGENXBIO says there is no clinical or pathological evidence yet to confirm their nature or cause.
- What wasn't found: no brain nodules or masses on any brain MRI.
- How it was found: an expanded brain-and-spine MRI monitoring plan REGENXBIO added a few months earlier, in response to a separate clinical hold on RGX-111, its related MPS I program.
- What happens now: periodic imaging only for the five patients; REGENXBIO does not expect to resubmit RGX-121's BLA in the near term.
How the finding was actually caught
This story starts with a different drug. In January 2026, the FDA placed a clinical hold on RGX-111, REGENXBIO's related gene therapy for MPS I, after a tumor was found in a patient in that trial.
The FDA held RGX-121 alongside it at the time. The rationale: similarities between the two therapies, their study populations, and their risk profiles — even though the safety signal had only appeared in RGX-111.
In response, REGENXBIO built an expanded MRI monitoring plan for RGX-121, covering both brain and spine imaging. That is a meaningfully broader check than what the field normally runs.
Spine MRI isn't standard practice in MPS trials. REGENXBIO added it anyway — and it's what caught this.
REGENXBIO's own release is explicit on this point: spine MRI is not normally conducted for MPS in clinical practice or trials. So the underlying prevalence and clinical significance of a finding like this, in this patient population, is unknown. Nobody had a reason to expect this specific check would turn anything up.
That is close to the opposite of the failure pattern behind GTC's recent coverage of undisclosed trial deaths in China. There, the problem was monitoring and disclosure that were too thin to catch real harm for months. Here, monitoring built for a different reason caught an unconfirmed, likely-benign finding that a narrower protocol would probably have missed entirely.
What the data does and doesn't show
A "small nodule" is a small lump; a "small cystic mass" is a small fluid-filled sac. Neither term, on its own, means something is actively harmful. Investigators deemed the findings nonserious, and radiologists believe they are likely benign.
REGENXBIO is careful not to overstate that read: there is no clinical or pathological evidence yet to confirm the nature or cause of the spine findings. That is an honest "we don't fully know" statement, not spin, and it cuts in both directions — likely benign is not the same as confirmed benign.
No brain nodules or masses were identified on any brain MRI. That distinction matters, because RGX-111's problem was a confirmed brain tumor; RGX-121's finding is confined to the spine and remains unconfirmed as anything at all.
All five participants continue to do well clinically, with overall stability to improvement on neurocognitive and neurobehavioral assessments. Investigators plan to continue observing them with periodic imaging only — no other intervention.
RGX-121's rollercoaster year
January 2026 brought the first hold, on both RGX-111 and RGX-121. February 2026 brought a rejection: the FDA turned down RGX-121's original BLA.
By June 2026, the agency had reversed course. It told REGENXBIO its existing trial data would be sufficient for resubmission under the accelerated approval pathway.
The company had planned to refile in the third quarter.
Instead, August 24, 2026 brought this new hold. REGENXBIO and NS Pharma are now evaluating additional patient imaging and longer-term follow-up data.
They say they will factor in FDA feedback, including the full clinical hold letter once received, before deciding RGX-121's next steps.
What this means for patients and families
MPS II is a rare, X-linked lysosomal storage disease.
Roughly 2,000 patients are diagnosed worldwide. More than 500 babies are born with it each year, most with the severe form and developmental delay apparent by 18 to 24 months.
RGX-121 is designed as a one-time therapy. It delivers a working copy of the IDS gene directly into the CNS, via intracisternal or intraventricular administration. The aim is a permanent source of I2S protein beyond the blood-brain barrier.
It carries Orphan Drug, Rare Pediatric Disease, Fast Track, and RMAT designations from the FDA, plus ATMP classification from the EMA. That regulatory support package reflects how few real options exist for this disease today.
For families in or considering CAMPSIITE, the headline (another hold) sounds alarming.
But the underlying finding may be more reassuring: nonserious, likely benign, and paired with patients who remain clinically stable to improving.
What this means for drug developers
The practical lesson for anyone running or evaluating a CNS-delivered AAV gene therapy program is simple: monitoring scope is now its own diligence variable.
Not just the topline adverse-event count. What imaging protocol is running, why it was added, and what it might catch — these matter as much as the safety table in a press release.
The FDA's willingness to hold RGX-121 alongside RGX-111 in January is the sharpest version of that lesson.
The tumor signal only showed up in RGX-111. Yet the agency treated capsid, route-of-administration, and population similarity as grounds for cross-program caution, not asset-by-asset review.
Any program sharing those characteristics with a troubled sibling should expect the same scrutiny — whether or not its own trial has produced a signal yet.
If you've solved a problem like this, Capsid/Vector Engineering & Tropism experts get matched to paid consulting work through GTC's Expert Network — join free.
REGENXBIO's own CEO draws a bright line around where that scrutiny stops. Curran Simpson, President and CEO, said: "We believe these findings are unique and limited to our Hunter Syndrome program, and require longer-term follow-up and additional data analysis to assess the benefit-risk profile of RGX-121. We remain focused on our Duchenne and retinal disease candidates, which utilize a different capsid and routes of administration, with near-term catalysts that are on track, including the planned submission of the Duchenne BLA this quarter and the wet AMD topline pivotal data announcement in the fourth quarter."
Independent perspective on the finding itself came from Roberto Giugliani, M.D., Ph.D. He is Professor in the Department of Genetics, UFRGS, and the Medical Genetics Service, HCPA, Porto Alegre, Brazil.
He said: "Boys with neuronopathic MPS II experience a multitude of neurodevelopmental and systemic effects. While imaging natural history is limited for this ultra-rare disease, I believe that asymptomatic, likely benign findings like these may be inherent to the impact of Hunter Syndrome throughout the body. I am pleased that these patients are doing well and remain asymptomatic."
What this means for investors
REGENXBIO's stock dropped sharply on the news.
BioSpace reported 22% down in premarket trading Monday. BioPharma Dive reported more than 25% down in early Monday trading. Fierce Biotech put the move at 24%, from Friday's $10.72 close to $8.17.
The figures differ by outlet and timing, but the direction and scale are consistent: a real, sharp move.
REGENXBIO shares fell 22% to more than 25% in premarket and early Monday trading.
The wider pipeline context matters here. REGENXBIO's AAV platform is the same platform basis behind Novartis' approved Zolgensma®.
Beyond RGX-121, the late-stage pipeline includes RGX-202 for Duchenne muscular dystrophy (BLA planned this quarter) and surabgene lomparvovec (ABBV-RGX-314) for wet AMD, developed with AbbVie (pivotal topline expected Q4 2026).
Both use a different capsid and route of administration than RGX-121 — REGENXBIO's stated reason for expecting the hold to stay contained to Hunter syndrome.
For anyone pricing REGENXBIO, or a comparable AAV CNS-delivery platform more broadly, the useful question isn't only "is this one asset delayed." It's whether the market is correctly separating asset-specific risk from platform-level risk.
Should a capsid- or route-sharing program elsewhere be priced differently because of this spine finding?
What this means for a CGT program
GTC analysis: a submission timeline that treats a favorable regulatory signal as final carries no contingency for a second, unrelated finding. That gap is the real planning risk, not the finding itself.
GTC analysis: the fix is building that contingency into the regulatory timeline before a first hold happens, not waiting for one to force the question.
Frequently asked questions
What happened to REGENXBIO's RGX-121?
The FDA placed a new clinical hold on RGX-121, REGENXBIO's gene therapy for Hunter syndrome, on August 24, 2026.
Five of 48 participants in the CAMPSIITE trial developed asymptomatic spine MRI findings 3 to 6 years after treatment. REGENXBIO does not expect to resubmit RGX-121's Biologics License Application in the near term.
What did the spine MRI findings actually show?
A small nodule or small cystic mass was found on spine MRIs of five participants. Investigators deemed the findings nonserious, and radiologists believe they are likely benign, though REGENXBIO says there is no clinical or pathological evidence yet to confirm their nature or cause. No brain nodules or masses were found on any brain MRIs, and all five patients remain clinically stable to improving.
How was this finding actually discovered?
REGENXBIO added an expanded brain-and-spine MRI monitoring plan to RGX-121 a few months earlier.
This was in direct response to a separate January 2026 clinical hold triggered by a tumor in RGX-111, REGENXBIO's related gene therapy for MPS I.
Spine MRI is not normally performed in MPS clinical trials or practice, so this finding would likely not have been caught under standard monitoring.
What happened to RGX-121 earlier in 2026?
The FDA rejected RGX-121's original Biologics License Application in February 2026.
Then in June 2026, it told REGENXBIO its existing trial data would be sufficient for resubmission under the accelerated approval pathway.
REGENXBIO had planned to refile before this new clinical hold arrived instead.
How did the market react, and is REGENXBIO's other pipeline affected?
REGENXBIO shares fell as much as 25% in premarket and early Monday trading, based on reporting from BioSpace, BioPharma Dive, and Fierce Biotech. CEO Curran Simpson said the company remains focused on its Duchenne program (RGX-202, BLA submission planned this quarter).
Also on its wet AMD program with AbbVie (surabgene lomparvovec/ABBV-RGX-314, pivotal topline expected Q4).
Both use a different capsid and routes of administration than RGX-121.
AAV to AI, Edition 02
Get the weekly resource
Three signals across four published stories, with decision context to help CGT teams act earlier.
Free PDF, 40 pages.
Download Edition 02Sources
- REGENXBIO Announces Regulatory Update on RGX-121 for MPS II — REGENXBIO press release (Form 8-K, Exhibit 99.1), U.S. Securities and Exchange Commission, August 24, 2026
- Safety concerns spur FDA to again halt testing of Regenxbio gene therapy — BioPharma Dive, August 24, 2026
- REGENXBIO's Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans — BioSpace, August 24, 2026
- Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings — Fierce Biotech, August 24, 2026
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.